Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals To Present Data On Etripamil At The American College Of Cardiology And European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24), to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA), to be held April 7-9th in Berlin, Germany. The presentations will be available following the embargo at
專注於創新心血管藥物開發和商業化的生物製藥公司Milestone Pharmicals Inc.（納斯達克股票代碼：MIST）今天宣佈，它將在本月即將舉行的兩次心臟病學會議上公佈有關依曲帕米的數據。該公司將在4月6日至8日在佐治亞州亞特蘭大舉行的美國心臟病學會年會（ACC24）上發表口頭和海報演講，並在4月7日至9日在德國柏林舉行的歐洲心律協會（EHRA）年會上發表海報演講。禁運結束後，演示文稿將在以下網址公佈
|
ACC Presentation Details: | ||
| Oral Presentation Title: | Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303) | |
| Presenter: | James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital | |
| Date and time: | Monday, April 8, 2024, 11:36 – 11:46 a.m. EDT | |
| Poster Presentation Title: | Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms | |
| Presenter: | James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital | |
| Date and time: | Sunday, April 7, 2024, 12:15 – 1:00 p.m. EDT | |
| EHRA Presentation Details: | ||
| Poster Presentation Title: | Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes | |
| Presenter: | David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc. | |
| Date and time: | Sunday, April 7, 2024, 10:15 a.m. CET | |
| ACC 演示詳情： | ||
| 口頭陳述標題： | 多中心、開放標籤的研究，探討在沒有監督的情況下自行給藥治療多發有症狀的室上性心動過速的Etripamil鼻腔噴霧劑的療效和安全性（第三階段，NODE-303） | |
| 演示者： | James Ip，醫學博士，紐約長老會醫院威爾康奈爾醫學院心臟病學部心臟起搏和植入設備教授兼主任 | |
| 日期和時間： | 美國東部時間 2024 年 4 月 8 日星期一上午 11:36 — 11:46 | |
| 海報演示文稿標題： | 在RAPID研究中，以症狀提示、自行給藥的鼻內注射埃曲帕米用於終止陣發性室上性心動過速：依曲帕米爾誘導的心動過速率降低、轉化爲鼻竇心律和患者症狀改善之間的關係 | |
| 演示者： | James Ip，醫學博士，紐約長老會醫院威爾康奈爾醫學院心臟病學部心臟起搏和植入設備教授兼主任 | |
| 日期和時間： | 美國東部時間 2024 年 4 月 7 日星期日下午 12:15 — 1:00 | |
| EHRA 演示詳情： | ||
| 海報演示文稿標題： | 通過患者感知的發作持續時間、症狀和嚴重程度來描述陣發性室上性心動過速發作：患者報告的縱向結果 | |
| 演示者： | 大衛·巴魯查，醫學博士，FACC，Milestone Pharmicals, Inc.首席醫學官 | |
| 日期和時間： | 歐洲中部時間 2024 年 4 月 7 日星期日上午 10:15 | |